JANE E. SISK, Ph.D.; RICHARD K. RIEGELMAN, M.D., Ph.D.
SISK JE, RIEGELMAN RK. Cost Effectiveness of Vaccination Against Pneumococcal Pneumonia: An Update. Ann Intern Med. 1986;104:79-86. doi: 10.7326/0003-4819-104-1-79
Download citation file:
Published: Ann Intern Med. 1986;104(1):79-86.
We updated a 1978 cost-effectiveness analysis of vaccination against pneumococcal pneumonia in light of the introduction in 1983 of a 23-valent vaccine, recent medical literature, and different relative prices of medical services. Although other base-case assumptions have remained reasonable, the low estimates of 10% of pneumonia as pneumococcal and a 3-year duration of immunity now appear more likely. Vaccination of a person age 65 or older could gain a year of healthy life for about $6000 in 1983 dollars. Medicare has covered pneumococcal vaccination since 1981. With the revised assumptions, net Medicare expenditures ranged from about $5.50 to $10.50 per vaccination, or from $4400 to $8300 per year of healthy life gained. Vaccination of an elderly person would almost break even, if duration of immunity were 8 years and would be cost saving if the vaccine were administered under a public program. Current levels of vaccination appear too low considering the potential health benefits and cost-effectiveness.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, Pneumonia, Prevention/Screening, Pulmonary/Critical Care, Streptococcal Infections.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only